ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
| ENZ Stock | USD 0.55 0.04 7.84% |
Slightly above 56% of all Enzo Biochem's investors are looking to take a long position. The analysis of overall sentiment of trading Enzo Biochem stock suggests that some investors are interested at this time. Enzo Biochem's investing sentiment can be driven by a variety of factors including economic data, Enzo Biochem's earnings reports, geopolitical events, and overall market trends.
Enzo |
Enzo Biochems overall topline benefits from revenue growth in the majority of its geographic regions.
Read at zacks.com
 |
Enzo Biochem Fundamental Analysis
We analyze Enzo Biochem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzo Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzo Biochem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Enzo Biochem is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Enzo Biochem Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enzo Biochem stock to make a market-neutral strategy. Peer analysis of Enzo Biochem could also be used in its relative valuation, which is a method of valuing Enzo Biochem by comparing valuation metrics with similar companies.
Peers
Enzo Biochem Related Equities
| BNR | Burning Rock | 13.03 | ||||
| STIM | Neuronetics | 11.79 | ||||
| DRIO | DarioHealth Corp | 7.69 | ||||
| BDSX | Biodesix | 3.13 | ||||
| SHC | Sotera Health | 0.37 | ||||
| XGN | Exagen | 0.94 | ||||
| FONR | Fonar | 0.98 | ||||
| CSTL | Castle Biosciences | 1.05 | ||||
| SERA | Sera Prognostics | 5.62 |
Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.